Microbiome as a treatment option in PAH

Presented at PVRI 2026 Congress by Thenappan Thenappan, University of Minnesota

Summary

Microbiome impacts pulmonary arterial hypertension (PAH) via gut dysbiosis, marked by pro-inflammatory bacteria. Research indicates that microbiota transplants could enhance PAH outcomes. A recent trial confirmed safety and feasibility, with future studies planned to improve donor engraftment and investigate dietary changes. The connection between gut health and PAH is intricate, with inflammation being a key factor. Ongoing research seeks to identify causative elements and refine treatment strategies.

Generated by AI, edited by PVRI